Assistance Publique - Hôpitaux de Paris
aphp.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
3,516
Active
942
Phase 3
462
Total enrollment
44,708,911
Pipeline matrix
Showing 40 of 355 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Standard of care | — | — | — | 5 | |||
| Apixaban | — | — | — | — | 3 | ||
| Rituximab | — | — | 21 | ||||
| Aspirin | — | — | — | — | 6 | ||
| Rivaroxaban group | — | — | — | — | — | 1 | |
| Evolocumab 140 MG/ML | — | — | — | — | — | 1 | |
| Anhydrous Amiloride Hydrochloride | — | — | — | — | — | 1 | |
| 14-day antibiotic therapy | — | — | — | — | — | 1 | |
| 28-day antibiotic therapy | — | — | — | — | — | 1 | |
| Course of amoxicillin | — | — | — | — | — | 1 | |
| IV Antibacterial Agents | — | — | — | — | — | 1 | |
| Orally antibacterial agents | — | — | — | — | — | 1 | |
| Ferric carboxymaltose IV | — | — | — | — | — | 1 | |
| TIMOFÉROL® | — | — | — | — | — | 1 | |
| continuous pivotal βL-AB | — | — | — | — | — | 1 | |
| intermittent pivotal βL-AB | — | — | — | — | — | 1 | |
| AG infusion most 1 dose | — | — | — | — | — | 1 | |
| AG infusion for 5 days | — | — | — | — | — | 1 | |
| Experimental group | — | — | — | — | — | 1 | |
| Control group | — | — | — | — | — | 1 | |
| Continuation of OMA treatment | — | — | — | — | — | 1 | |
| Prednisone | — | — | 12 | ||||
| Tocilizumab | — | — | — | — | 12 | ||
| Baricitinib | — | — | — | — | 5 | ||
| Fecal Microbiota Transplantation | — | — | — | — | 4 | ||
| Adalimumab | — | — | — | — | 7 | ||
| Anakinra | — | — | — | — | 6 | ||
| Metformin | — | — | — | — | 4 | ||
| Chemotherapy | — | — | — | — | 4 | ||
| standard antibiotic therapy | — | — | — | — | — | 2 | |
| Sham-transplantation | — | — | — | — | 2 | ||
| Tadalafil | — | — | — | — | — | 2 | |
| Dexamethasone | — | — | — | 7 | |||
| Letermovir | — | — | — | — | 3 | ||
| Morphine | — | — | — | — | 3 | ||
| Valacyclovir | — | — | — | — | 2 | ||
| Mycophenolate mofetil | — | — | — | — | — | 4 | |
| Apixaban 5 MG | — | — | — | — | — | 2 | |
| Gentamicin | — | — | — | — | 2 | ||
| Valganciclovir | — | — | — | — | — | 2 |
315 more active programs hidden
Next readouts
- 2022-04
- 2024-02-28
- 2024-05
- 2024-06
- 2024-09
- 2025-01-29
- 2025-03-03
- 2025-04-01
- 2025-04-09
- 2025-05-15
Top conditions
- COVID-1933
- Obesity33
- Sickle Cell Disease30
- Cystic Fibrosis28
- Covid1924
- Breast Cancer23
- Rheumatoid Arthritis21
- Hepatocellular Carcinoma20
Frequently asked questions about Assistance Publique - Hôpitaux de Paris
- How many clinical trials does Assistance Publique - Hôpitaux de Paris have on ClinicalTrials.gov?
- Assistance Publique - Hôpitaux de Paris is listed as the lead sponsor on 3,516 clinical trials in ClinicalTrials.gov, 942 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Assistance Publique - Hôpitaux de Paris's trials are in Phase 3?
- 462 of Assistance Publique - Hôpitaux de Paris's trials are in Phase 3, spread across 355 active drug programs.
- What therapeutic areas does Assistance Publique - Hôpitaux de Paris focus on?
- Assistance Publique - Hôpitaux de Paris's most-studied conditions on ClinicalTrials.gov are COVID-19, Obesity, Sickle Cell Disease, Cystic Fibrosis, Covid19.
- When are Assistance Publique - Hôpitaux de Paris's next clinical trial readouts?
- Assistance Publique - Hôpitaux de Paris has 10 upcoming primary-completion readouts tracked here; the soonest is “A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents”, expected around 2022-04.